ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) Financial Survey

ObsEva (NASDAQ:OBSV) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.

Profitability

This table compares ObsEva and Tharimmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Tharimmune	N/A	-167.63%	-130.18%

Institutional and Insider Ownership

17.5% of ObsEva shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Comparatively, 2.4% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.

Valuation & Earnings

This table compares ObsEva and Tharimmune”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	$20.11 million	0.00	-$58.38 million	($0.92)	N/A
Tharimmune	N/A	N/A	-$9.32 million	N/A	N/A

Tharimmune has lower revenue, but higher earnings than ObsEva.

Analyst Recommendations

This is a summary of recent ratings and target prices for ObsEva and Tharimmune, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0	0	0	0	0.00
Tharimmune	0	0	1	1	3.50

Tharimmune has a consensus target price of $17.00, suggesting a potential upside of 1,025.83%. Given Tharimmune’s stronger consensus rating and higher possible upside, analysts plainly believe Tharimmune is more favorable than ObsEva.

Summary

Tharimmune beats ObsEva on 7 of the 11 factors compared between the two stocks.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

About Tharimmune

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.